Business Wire

Taktikal Secures $2 Million Funding from Brunnur Ventures to Drive International Sales Expansion

13.1.2022 01:19:00 EET | Business Wire | Press release

Share

Taktikal (www.taktikal.io), a developer of next generation digital trust solutions, announced that Brunnur Ventures had invested $2 million into the company to drive customer acquisition and the international build out of its business strategy. Taktikal provides enterprise-grade electronic signatures solutions to meet the growing need for companies to automate and streamline processes that require identification, authentication, and authorisation. Taktikal leverages deep expertise with the state-level authentication infrastructure of Nordic nation states such as Iceland to offer faster processing, greater efficiency in document management, reduced operational risk and a better customer experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006022/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Taktikal CEO Valur Thor Gunnarsson (Photo: Business Wire)

New funding will accelerate international sales expansion of the Company’s e-signature software suite into the global SME market, where ad hoc, low security, home-baked processes are pervasive today.

“We’re delighted to announce the close of our first institutional investment round, with participation by Brunnur Ventures, whom we welcome as experienced and valued shareholders in the Company for the next phase of our development,” says Taktikal’s CEO Valur Gunnarsson, “People are commonly emailing sensitive documents such as passport and driver’s license scans in a highly insecure way. Taktikal brings out-of-the-box enterprise-grade document signing and other processes to a vast potential customer base of corporates needing to provide best-in-class workforce and customer onboarding experiences, and driven by increasing security, as well as AML, KYC, PEP and sanctions requirements.”

“To be successful, businesses must find ways to streamline operations and reduce administrative bottlenecks. Taktikal offers an outstanding service to meet these needs,” commented Kjartan Olafsson, Investment Manager at Brunnur Ventures who will take a seat in Taktikal’s board, “We believe that a transformation is overdue in this space akin to the revolution we’ve seen in many other workflow areas such as CRM and project management.”

ABOUT TAKTIKAL

Taktikal ehf, based in Iceland is a leading vendor of next generation enterprise grade electronic signature solutions, covering application-level integrated smart forms, in-browser fill-and-sign, and email. The Company serves a growing need for secure, best-in-class process to support corporate requirements for automated customer and workforce onboarding, KYC and AML processes and in-application electronic identity.

For more information please visit: www.taktikal.io

ABOUT BRUNNUR VENTURES

Brunnur Ventures is venture capital firm based in Iceland focused on seed and early-stage investments, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.

Brunnur Ventures currently manages two funds, Brunnur I and Brunnur II, with fund operation and administration provided by Landsbref, a fund management company licensed by the Icelandic Financial Supervisory Authority.

For more information please visit:www.brunnurventures.com

Forward-Looking Statements

This press release may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The information in this presentation is subject to updating, completion, revision, further verification, and amendment without notice and the Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Valur Gunnarsson
CEO, Taktikal ehf
Tel: [+354] 552 5620
E-mail: valur@taktikal.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye